Solasia, ZIOPHARM enter license and collaboration agreement for darinaparsin product

[News]

ZIOPHARM Oncology, Inc., an oncology small molecule and synthetic biology drug development company, and Solasia Pharma K.K., a developer of Western oncology pharmaceuticals in-licensed for commercialization in Asian markets, announced today that they have entered into a license and collaboration agreement to develop and commercialize ZIOPHARM's darinaparsin product and related organic arsenic molecules in specified Pan-Asian/Pacific territories.

More... (http://www.news-medical.net/news/20110307/Solasia-ZIOPHARM-enter-license-and-collaboration-agreement-for-darinaparsin-product.aspx)